Delivery Order SPE2DR25D1109-SPE2DR26FFL0S
- Not listed
- This delivery order, valued at $1,227.88 and awarded on January 12, 2026, procures Lantus SoloStar 100 Unit/mL 3mL insulin pens for the Defense Logistics Agency (DLA). The award was made to AmerisourceBergen Drug Corp, the corporate office division of Cencora, Inc., on a firm fixed-price basis with no set-aside designation, indicating open and competitive award. Performance will be executed in Conshohocken, Pennsylvania, with an ultimate completion date of January 13, 2026. This delivery order...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on September 16, 2025, for Lantus SoloStar 100 Unit/mL insulin pens with a ceiling value of $1,022.80. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of September 17, 2025, issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical...
- AmerisourceBergen Drug Corp has been awarded a competitively competed delivery order by the Defense Logistics Agency (DLA) for Lantus SoloStar 100 Unit/ML insulin pens, valued at $1,294.28. The order, issued on November 12, 2025, with an ultimate completion date of November 13, 2025, represents a firm fixed price transaction with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this delivery requirement from its corporate office location....
- The Defense Logistics Agency (DLA) awarded a $1,839.84 delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens on December 18, 2025, with an ultimate completion date of December 19, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement needs,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $1,994.33 delivery order for Lantus SoloStar 100 Unit/ML 3ML insulin pens, with a completion date of December 23, 2025. This competitively awarded, non-set-aside contract reflects a firm fixed price arrangement and represents a routine pharmaceutical procurement to support federal medical supply needs. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on January 5, 2026, for the supply of Lantus SoloStar 100 Unit/ML 3ML insulin pens, with a contract ceiling value of $1,485.00. This is a firm fixed price delivery order under a non-set-aside competitive procurement, with an ultimate completion date of January 6, 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under...
- On January 9, 2026, the Defense Logistics Agency awarded a delivery order valued at $1,008.75 to AmerisourceBergen Drug Corp for the supply of Lantus SoloStar 100 Unit/mL 3mL insulin pens. The award was made on a firm fixed-price basis with no set-aside designation, indicating full and open competition. Performance will be completed by January 12, 2026, with fulfillment based in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's parent company, Cencora, Inc.,...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Lantus SoloStar 100 Unit/mL 3mL insulin pens with a ceiling value of $4,398.30. The contract is structured as a firm fixed price delivery order with no set-aside designation, indicating competitive award. Performance will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion...
- The Defense Logistics Agency awarded a delivery order valued at $1,095.17 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL insulin pens on December 18, 2025, with completion scheduled for December 19, 2025. This non-competitive, firm fixed-price delivery order was issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 1, 2025, for the supply of Lantus SoloStar 100 Unit/ML 3ML insulin pens, valued at $1,312.94. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of December 2, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement across...
- SPE2DR25D1109Indefinite Delivery Contract
- SPE2DR25D1109-SPE2DR26FFL0SDelivery Order
This delivery order, awarded on January 20, 2026, is for Lantus SoloStar 100 Unit/mL insulin pens valued at $1,168.14 and issued to AmerisourceBergen Drug Corp by the Defense Logistics Agency (DLA). The order represents a competitive award with no set-aside designation and carries a firm fixed-price structure with an ultimate completion date of January 21, 2026. AmerisourceBergen, operating under parent company Cencora, Inc., serves as a critical pharmaceutical distributor supporting federal medical procurement needs, with performance occurring at the company's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 2026. The IDC functions as a comprehensive global pharmaceutical support vehicle enabling the company to supply an extensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. The arrangement reflects DLA's reliance on established vendor relationships to efficiently fulfill critical medication requirements across the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 1/19/26 |